Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Session highlights: clonal hematopoiesis in multiple myeloma

Niccolò Bolli • 25 Aug 2022
IMS 2022
Multiple Myeloma Lenalidomide

In this video, Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, shares some highlights from a session held at IMS 2022, which focused on the role of clonal hematopoiesis (CH) in multiple myeloma, and comments on the importance of better understanding CH and how it contributes to disease pathogenesis. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Niccolò Bolli

2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
2:52
Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
Niccolò Bolli • 25 Sep 2022
2:45
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli • 25 Aug 2022
4:02
The association between CHIP and MGUS
Niccolò Bolli • 12 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals